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LETTER TO THE EDITOR
Learning from experience. Proposal of a refined
definition and staging system for bisphosphonate-related
osteonecrosis of the jaw (BRONJ)
Dear Editor,
It is the authors’ belief that the internationally
accepted deﬁnition of bisphosphonate-related osteone-
crosis of the jaws (BRONJ) (Ruggiero et al, 2009) has
several limitations that prevent clinicians from being
conﬁdent with the diagnosis of the disease. Following
recognition of the non-exposed BRONJ clinical variant
(Lazarovici et al, 2009), we all became aware that the
presence of exposed necrotic bone in the oral cavity’, as
outlined in the American Association of Oral and
Maxillofacial Surgery (AAOMS) case deﬁnition, is just
one of the possible clinical manifestations of BRONJ
and is not found in all BRONJ patients. As bone
exposure’ is certainly not the initial sign of BRONJ in
most patients and a minimum of 6–8 weeks’ persistence
is required to conﬁrm the clinical suspicion, the ﬁnal
diagnosis is usually delayed for several weeks or months.
Therefore, to date, it has been almost impossible to
study the early phases of BRONJ. This delayed
diagnosis can also explain, at least in part, why the
disease is often refractory to the medical and surgical
treatments commonly used.
We believe that clinicians will beneﬁt from a deﬁnition
of BRONJ that contains only robust information, without
considering any deﬁnite clinical picture or a binding time-
frame (i.e. 6–8 weeks). As qualiﬁed members of the
Expert Panel of the Italian Society for Maxillofacial
Surgery (SICMF) and the Italian Society of Oral Pathol-
ogy and Medicine (SIPMO) on Bisphosphonate-Related
Osteonecrosis of the Jaws, we are submitting to the
attention of the scientiﬁc community the following
deﬁnition of BRONJ: bisphosphonate related osteonecrosis
of the jaw (BRONJ) is an adverse drug reaction described
as the progressive destruction and death of bone that affects
the mandible or maxilla of patients exposed to the treatment
with nitrogen-containing bisphosphonates, in the absence of
a previous radiation treatment’.
Along with this new deﬁnition of BRONJ, we set up
and propose a diagnostic work-up to be used to reach
the ﬁnal diagnosis.
Although exposed necrotic bone in the oral cavity still
remains the best indicator of BRONJ (Ruggiero et al,
2009), other non-speciﬁc signs and symptoms (Table 1)
should raise the suspicion of BRONJ, even in a patient
with a well-recognized dental or periodontal disease
(Fedele et al, 2010). In short, BRONJ should be always
investigated in a patient taking nitrogen-containing
bisphosphonates (NBP), when one or more clinical
signs are present. Because BRONJ is primarily a disease
that aﬀects the jawbone, we strongly believe that
radiological examination is an important step of the
diagnosis. However, as the radiological ﬁndings may be
characteristic not only of BRONJ (Khan et al, 2008),
these ﬁndings should always match the clinical picture,
in order to progress from the clinical suspicion to the
ﬁnal diagnosis. This is of outmost importance as bone
biopsies for histology are still not routinely advised for
the risk of worsening the disease process. A schematic
approach to the work-up for a diagnosis of BRONJ is
proposed (Scheme 1), where computed tomography
(CT) currently represents the most useful diagnostic
tool because of its widespread use and accessibility for
patients (Bianchi et al, 2007). Structural alteration of
trabecular bone is a consistent ﬁnding of CT scans
performed in patients with BRONJ (Table 2) (Arce et al,
2009). CT scans can clearly depict the degree of
osteosclerosis of the aﬀected site, visible as the loss of
contrast deﬁnition between the endosteal cortex and the
subjacent medullary bone (i.e. trabecular thickening
and⁄or regional or diﬀuse osteosclerosis), with respect to
the uninvolved bone tissue (Hutchinson et al, 2010).
Osteosclerosis seems to characterize the early stages of
disease and also precedes the occurrence of frank bone
exposure in the oral cavity (Saia et al, 2010), and thus it
should be searched for to provide an early diagnosis.
Even though magnetic resonance imaging (MRI)
provides more detailed information than CT on focal
bone marrow alterations (Bisdas et al, 2008), the former
could provide non-diagnostic results owing to magnetic
artifacts caused by the presence of dental casting alloys
(Shaﬁei et al, 2003) as well as to motion artifacts caused
by the prolonged time necessary to scan the head and
neck region (Lenz et al, 2000). The majority of BRONJ
cases could be diagnosed and staged correctly by the
combined use of clinical methods and CT, the latter
method currently being more cost-eﬀective and easily
accessible than MRI. On the other hand, we believe that
MRI should be used to evaluate cases diﬃcult to
identify with CT and to establish the real extent of
jawbone and soft-tissue involvement in BRONJ patients
who are candidates for surgical resection.
The staging system of a bone disease that relies on the
use of radiologic imaging for its diagnosis should also be
based on the common radiologic features of the disease.
The current AAOMS staging system (Ruggiero et al,
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2009; Migliorati et al, 2011), which assigns patients to
diﬀerent stages of disease on the basis almost exclusively
of clinical criteria, fails, in our opinion, to consider this
important aspect. In this regard, we set up a combined
clinical and radiological staging system with the aim of
pooling BRONJ patients in diﬀerent groups also based
on the radiological extent of the disease. The staging
system we propose (Table 3) diﬀers from the 2009
AAOMS classiﬁcation as follows:
1 The absence of Stage 0, so that BRONJ patients
with exposed and non-exposed necrotic bone sim-
ply represent distinct clinical pictures within the
same disease stage.
2 The description of three stages (1–3) based on
clinical and CT ﬁndings, where Stage 1 includes
patients with focal (alveolar bone) osteosclerosis,
Stage 2 includes patients with diffuse (alveolar and
basal bone) osteosclerosis and Stage 3 includes
patients with clinical and radiological signs of
advanced and complicated disease.
3 Pain and purulent discharge are no longer used to
distinguish between different disease stages. As these
symptoms deﬁne only asymptomatic (a) and symp-
tomatic (b) forms of BRONJ in patients within the
same stage, exclusion of pain and purulent discharge
as criteria would limit the ping-pong’ effect (the
migration of patients from Stage 1 to Stage 2, and
vice versa) that we all experienced when using the
AAOMS classiﬁcation, as a result of the repeated
use of antibiotic therapies to treat recurrent bone
infections and associated pain.
Table 2 Non-speciﬁc computed tomography (CT) ﬁndings associated
with bisphosphonate-related osteonecrosis of the jaws (BRONJ)
Early signs Late signs
Cortical disruption Diﬀuse osteosclerosisb
Focal bone marrow
sclerosisa
Oro-antral ﬁstula
Markedly thickened and
sclerotic lamina dura
Osteolysis extending to the
sinus ﬂoor
Persisting alveolar socket Osteosclerosis of adjacent
bones (zygoma, hard palate)
Trabecular thickeninga Pathologic fracture
Periosteal reaction
Prominence of the inferior
alveolar nerve canal
Sequestra formation Sinusitis
a Density in the sclerotic areas is limited to the alveolar bone region
and ranges from little to fully sclerotic with irregular compact and
disorganized trabeculation.
b Reduced or complete loss of contrast deﬁnition between the endosteal
cortex and subjacent medullary bone (density conﬂuence), involving
both the alveolar bone and the basal bone of the mandible and maxilla.
Table 1 Non-speciﬁc clinical signs associated with bisphosphonate-
related osteonecrosis of the jaws (BRONJ)
Major clinical sign
Exposed necrotic bone in the oral cavity
Minor clinical signs and symptoms
Abscess
Displaced mandibular stumps
Extra-oral ﬁstula
Gross mandible deformity
Hypoesthesia⁄paraesthesia of the lipsa
Mucosal⁄gengival ﬁstula
Nasal leakage of ﬂuids
Nonhealing postextraction socket
Purulent discharge
Spontaneous expulsion of sequestra and necrotic bone fragments
Sudden dental mobility
Swelling
Toothache and bone pain
Trismus
a Owing to inferior alveolar nerve⁄infraorbital nerve involvement.
Scheme 1 Diagnostic work-up for BRONJ. VAS, visual analogic scale
Table 3 Clinical and radiological staging system of bisphosphonate-
related osteonecrosis of the jaws (BRONJ)
Stage 1 Focal BRONJ
Clinical signs and symptoms: bone exposure; sudden dental
mobility; nonhealing postextraction socket; mucosal
ﬁstula; swelling; abscess formation; trismus; gross
mandibular deformity and⁄or hypoesthesia⁄paraesthesia of
the lips
CT ﬁndings: increased bone density limited to the
alveolar bone region (trabecular thickening and⁄or focal
osteosclerosis ), with or without the following signs:
markedly thickened and sclerotic lamina dura; persisting
alveolar socket; and⁄orcortical disruption
1a. Asymptomatic
1b. Symptomatic (pain and purulent discharge)
Stage 2 Diffuse BRONJ
Clinical signs and symptoms: same as Stage 1
CT ﬁndings: increased bone density extended to the basal
bone (diﬀuse osteosclerosis), with or without the
following signs: prominence of the inferior alveolar nerve
canal; periosteal reaction; sinusitis; sequestra formation;
and⁄or oro-antral ﬁstula
2a. Asymptomatic
2b. Symptomatic (pain and purulent discharge)
Stage 3 Complicated BRONJ
Same as Stage 2, with one or more of the following:
clinical signs and symptoms: extra-oral ﬁstula; displaced
mandibular stumps; nasal leakage of ﬂuids
CT ﬁndings: osteosclerosis of adjacent bones (zygoma,
hard palate); pathologic mandibular fracture; and⁄or
osteolysis extending to the sinus ﬂoor
CT, computed tomography.
Letter to the Editor
622
Oral Diseases
4 The presence of clinically detectable sequestra is no
longer regarded as a sign of complicated disease, as
it is for AAOMS Stage 3. In fact, it is a common
experience that the spontaneous expulsion or
surgical removal of bony sequestra often leads to
dramatic, albeit somewhat temporary, clinical
improvement, with mucosal epithelialization of
the affected site (Ferlito et al, 2011).
The deﬁnition, work-up and staging system proposed
here might, as a whole, provide several practical
beneﬁts, in the order: anticipated BRONJ diagnosis
and access of patients to therapies; a reduced need for
extensive surgical resections with associated long and
debilitating postoperative hospitalization; and increased
overall eﬃcacy of treatments and patients’ curability.
The disadvantage of the additional cost of bone imaging
(CT) for the diagnosis would be oﬀset against the overall
reduction in treatment costs.
When a new disease is found, little is known of its
medical features and behavior; this makes it necessary to
avoid general deﬁnitions that may include potentially
healthy patients (resulting in a higher false-positive risk).
This also occurred at the start, when the actual BRONJ
case deﬁnition was adopted.
At present, with the growing bulk of research on
BRONJ, we believe that it is necessary to enter a new
phase where clinicians try to establish the initial stages
of the disease process, in order to make an earlier
diagnosis and improve treatment eﬀectiveness.
Although adjustments and updating will be necessary
in the future, the deﬁnition, work-up and staging system
proposed here could achieve this purpose.
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